12:00 AM
 | 
Aug 03, 2009
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Access Pharmaceuticals, Milestone Biosciences, SpePharm sales and marketing update

Access said it ended a 2008 deal that gave Milestone exclusive rights to market MuGard in North America because Milestone failed to meet undisclosed...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >